Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 15 studies | 31% ± 16% | |
peripheral blood | 11 studies | 26% ± 12% | |
lung | 10 studies | 27% ± 8% | |
eye | 5 studies | 28% ± 12% | |
bone marrow | 4 studies | 27% ± 12% | |
heart | 4 studies | 20% ± 4% | |
liver | 4 studies | 34% ± 12% | |
intestine | 4 studies | 24% ± 7% | |
adipose | 4 studies | 22% ± 1% | |
placenta | 3 studies | 34% ± 2% | |
uterus | 3 studies | 28% ± 13% | |
skin | 3 studies | 23% ± 10% | |
kidney | 3 studies | 20% ± 4% | |
lymph node | 3 studies | 18% ± 1% | |
breast | 3 studies | 19% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 7093.60 | 1445 / 1445 | 100% | 54.80 | 183 / 183 |
intestine | 100% | 7444.40 | 966 / 966 | 100% | 28.55 | 527 / 527 |
ovary | 100% | 8608.35 | 180 / 180 | 100% | 55.64 | 430 / 430 |
prostate | 100% | 7940.19 | 245 / 245 | 100% | 24.33 | 502 / 502 |
skin | 100% | 8900.11 | 1809 / 1809 | 100% | 36.25 | 472 / 472 |
stomach | 100% | 5411.64 | 359 / 359 | 100% | 31.71 | 286 / 286 |
thymus | 100% | 7880.28 | 653 / 653 | 100% | 23.63 | 605 / 605 |
uterus | 100% | 8718.46 | 170 / 170 | 100% | 31.92 | 459 / 459 |
pancreas | 100% | 4348.14 | 328 / 328 | 99% | 24.17 | 177 / 178 |
breast | 100% | 7778.10 | 459 / 459 | 99% | 30.30 | 1111 / 1118 |
bladder | 100% | 7739.10 | 21 / 21 | 99% | 27.68 | 500 / 504 |
kidney | 100% | 5867.40 | 89 / 89 | 99% | 20.65 | 893 / 901 |
brain | 99% | 4345.59 | 2617 / 2642 | 100% | 27.34 | 705 / 705 |
lung | 100% | 8551.60 | 578 / 578 | 99% | 31.48 | 1139 / 1155 |
liver | 100% | 4866.56 | 226 / 226 | 99% | 17.22 | 400 / 406 |
adrenal gland | 100% | 6796.10 | 258 / 258 | 98% | 19.92 | 226 / 230 |
adipose | 100% | 7587.37 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 8584.51 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 26.30 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 29.35 | 29 / 29 |
muscle | 100% | 9260.03 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 8907.77 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 32.43 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 21.83 | 1 / 1 |
peripheral blood | 100% | 7135.73 | 927 / 929 | 0% | 0 | 0 / 0 |
heart | 99% | 5085.68 | 854 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006325 | Biological process | chromatin organization |
GO_0010971 | Biological process | positive regulation of G2/M transition of mitotic cell cycle |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0006974 | Biological process | DNA damage response |
GO_0050727 | Biological process | regulation of inflammatory response |
GO_0032968 | Biological process | positive regulation of transcription elongation by RNA polymerase II |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
GO_2000330 | Biological process | positive regulation of T-helper 17 cell lineage commitment |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005654 | Cellular component | nucleoplasm |
GO_0000794 | Cellular component | condensed nuclear chromosome |
GO_0005634 | Cellular component | nucleus |
GO_0019899 | Molecular function | enzyme binding |
GO_0003682 | Molecular function | chromatin binding |
GO_0000976 | Molecular function | transcription cis-regulatory region binding |
GO_0070577 | Molecular function | lysine-acetylated histone binding |
GO_0003712 | Molecular function | transcription coregulator activity |
GO_0106140 | Molecular function | P-TEFb complex binding |
GO_0140566 | Molecular function | histone reader activity |
GO_0008353 | Molecular function | RNA polymerase II CTD heptapeptide repeat kinase activity |
GO_0002039 | Molecular function | p53 binding |
GO_0099122 | Molecular function | RNA polymerase II C-terminal domain binding |
GO_0003713 | Molecular function | transcription coactivator activity |
GO_0005515 | Molecular function | protein binding |
Gene name | BRD4 |
Protein name | Bromodomain-containing protein 4 variant Bromodomain containing 4 BRD4 protein Bromodomain-containing protein 4 (Protein HUNK1) |
Synonyms | HUNK1 HUNKI hCG_2000917 MCAP CAP |
Description | FUNCTION: Chromatin reader protein that recognizes and binds acetylated histones and plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation . Remains associated with acetylated chromatin throughout the entire cell cycle and provides epigenetic memory for postmitotic G1 gene transcription by preserving acetylated chromatin status and maintaining high-order chromatin structure . During interphase, plays a key role in regulating the transcription of signal-inducible genes by associating with the P-TEFb complex and recruiting it to promoters . Also recruits P-TEFb complex to distal enhancers, so called anti-pause enhancers in collaboration with JMJD6 . BRD4 and JMJD6 are required to form the transcriptionally active P-TEFb complex by displacing negative regulators such as HEXIM1 and 7SKsnRNA complex from P-TEFb, thereby transforming it into an active form that can then phosphorylate the C-terminal domain (CTD) of RNA polymerase II . Regulates differentiation of naive CD4(+) T-cells into T-helper Th17 by promoting recruitment of P-TEFb to promoters (By similarity). Promotes phosphorylation of 'Ser-2' of the C-terminal domain (CTD) of RNA polymerase II . According to a report, directly acts as an atypical protein kinase and mediates phosphorylation of 'Ser-2' of the C-terminal domain (CTD) of RNA polymerase II; these data however need additional evidences in vivo . In addition to acetylated histones, also recognizes and binds acetylated RELA, leading to further recruitment of the P-TEFb complex and subsequent activation of NF-kappa-B . Also acts as a regulator of p53/TP53-mediated transcription: following phosphorylation by CK2, recruited to p53/TP53 specific target promoters . .; FUNCTION: [Isoform B]: Acts as a chromatin insulator in the DNA damage response pathway. Inhibits DNA damage response signaling by recruiting the condensin-2 complex to acetylated histones, leading to chromatin structure remodeling, insulating the region from DNA damage response by limiting spreading of histone H2AX/H2A.x phosphorylation. . |
Accessions | Q5BJ26 ENST00000597315.5 ENST00000679869.1 [O60885-1] ENST00000371835.8 [O60885-2] Q05BM2 Q6PIS5 M0QZD9 ENST00000360016.9 [O60885-3] ENST00000601941.1 ENST00000594841.5 O60885 M0QYW0 Q6NXE4 W8JJB1 ENST00000263377.6 [O60885-1] M0R0H4 |